### OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

FOURTH FLOOR
1755 SEPERSON DAVIS HIGHWAY
17 ABONGTON VIRGINIA 22202 U.S.A.
(703) 447-3000
(703) 447-3000
FRADENE ONPAT@OBLON.COM

WWW.OBLON.COM

PATENT, TRADEMARK AND COPYRIGHT LAW AND RELATED FEDERAL AND ITC LITIGATION

ATTN: APPLICATION BRANCH

NORMAN F. OBLON MARVIN J. SPIVAK C. IRVIN McCLELLAND GREGORY J. MAIER ARTHUR I. NEUSTADT RICHARD D. KELLY JAMES D. HAMILTON **ECKHARD H. KUESTERS ROBERT T. POUS** DAVID J. KERA **CHARLES L. GHOLZ** VINCENT J. SUNDERDICK\* WILLIAM E. BEAUMONT STEVEN B. KELBER\* **ROBERT F. GNUSE** JEAN-PAUL LAVALLEYE, PH.D. JEFFREY H. KAUFMAN BRIAN D. ANDERSON **ROBERTA S. BREN** JOHN H. WEBER STEPHEN G. BAXTER, PH.D. MARTIN M. ZOLTICK ROBERT W. HAHL, PH.D. RICHARD L. TREANOR, PH.D. STEVEN P. WEIHROUCH JOHN T. GOOLKASIAN\* MARC R. LABGOLD, PH.D.\* WILLIAM J. HEALEY, PH.D.\* RICHARD L. CHINN, PH.D. STEVEN E. LIPMAN **CARL E. SCHLIER** P. JAY HINES JAMES J. KULBASKI CATHERINE B. RICHARDSON\* RICHARD A. NEIFELD, PH.D. J. DEREK MASON, PH.D.

GERALD J. MOSSINGHOFF

MILTON STERMAN
SAMUEL H. BLECH\*
JOHN O. TRESANSKY\*
ALTON D. ROLLINS
JAMES R. BOLER\*
HARRIS A. PITLICK\*
RAYMOND F. CARDILLO, JR.
MASAYASU MORI<sup>†</sup>

**SURINDER SACHAR JONATHAN HUDIS** LINDSEY A. DODSON\* FRANK J. WEST\* SHARON E. CRANE, PH.D.\* BRADLEY D. LYTLE JOHN W. CARPENTER CHRISTINA M. GADIANO KARL D. KOVACH\* MICHAEL H. JACOBS THOMAS M. RIZZO, PH.D.\* JEFFREY B. McINTYRE\* KATHLEEN COONEY-PORTER\* ANDREW M. OLLIS MARGO LIVESAY, PH.D.\* FREDERICK D. VASTINE, PH.D.\* PAUL E. RAUCH, PH.D.º MICHAEL R. CASEY, PH.D.\*

\* BAR MEMBERSHIP OTHER

THAN VIRGINIA
\* REGISTERED PATENT AGENT

**† JAPANESE BENRISHI** 

## THIS IS A RESPONSE TO A DEREK MASON, PH.D. NOTICE TO FILE MISSING PARTS OF APPLICATION

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Re: 7063-001-0

Inventor: Renata Maria Anna CAVALIERE VESELY et al

Serial No: 08/813,776 Filed: March 7, 1997

STRAINS OF BACTERIA AND PHARMACEUTICAL

COMPOSITION CONTAINING ONE OR MORE OF SUCH STRAINS AND USE OF SAME FOR PREVENTING AND TREATING DISEASES ASSOCIATED WITH OR CAUSED BY

ALTERED METABOLISM OF BILE ACIDS

SIR:

Attached hereto for filing are the following papers:

For:

PETITION FOR THREE-MONTH EXTENSION OF TIME, FILING OF DECLARATION UNDER 37 CFR 1.53(D), EXECUTED DECLARATION, RETURN COPY OF FORM PTO-1533 (Notice to File Missing Parts of Application)

Our check in the amount of \$1,252.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stephen G. Baxter, Ph.D. Registration No. 32,884



EPARTMENT OF COMM UNITED Patent and ... ademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

OBLON, SPIVAK, McCLELLAND MAIER & NEUSTADT, P.C. APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO TITLE

NOT ASSIGNED

プロを思ったりまった

08/813,776 03/07/97 CAVALIERE VESSLY

0262/0521

DBLON SPIVAK MCCLELLAND MAIER & NEUSTADT

FOURTH FLOOR

1755 JEFFERSON DAVIS HWY ARLINGTON VA 22202

1815 **DATE MAILED:** 

Decl Fees/50g

## NOTICE TO FILE MISSING PARTS OF APPLICATION

Filing Date Granted

An Application Number and Filing Date have been assigned to this application. However, the items indicated below are missing. The required items and fees identified below must be timely submitted ALONG WITH THE PAYMENT OF A SURCHARGE for items 1 and 1 for a 🗗 large entity 🗆 small entity in compliance with 37 CFR 1.27. The surcharge is set forth in 37 CFR 1.16(e). Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file all required items and pay any fees required above to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

'If all required items on this form are filed within the period set above, the total amount owed by applicant as a "⚠/large entity 🗆 small entity (verified statement filed), is \$ REASTITED PHYLLENIC GHIND 45 POIS Name/Numberr 98813776 FC: 704 insufficient.\$110.00 CR LIZAR PROPORTS WAN ELECTRONICO SONO BETHING Applicant-must-submit \$ statement claiming such status (37 CFR 1.27). 130.00 CH □ 2. Additional claim fees of \$ , including any multiple dependent claim fees, are required. Applicant must either submit the additional claim fees or cancel additional claims for which fees are due. is missing. does not cover the newly submitted items. does not identify the application to which it applies. does not include the city and state or foreign country of applicant's residence. 🐧 n oath or declaration in compliance with 37 CFR 1. 63, including residence information and identifying the application by The above Application Number and Filing Date is required. 4. The signature(s) to the oath or declaration is/are: missing. by a person other than inventor or person qualified under 37 CFR 1.42, 1.43, or 1.47. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required. Ad justment States significations of the Tolking joint inventor(s) is missing from the oath or declaration: 10729/1997 JTIPPETT 00000045 08813776 An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this application by 04 FC:103 the above Application Number and Filing Date, is required. 응음음 processing fee is required since your check was returned without payment (37 CFR 1 214mg □ 6. A \$ ☐ 7, Your filing receipt was mailed in error because your check was returned without payment. 8. The application does not comply with the Sequence Rules. JIIPPETT 00000045 08813

See attached "Notice to Comply with Sequence Rules 37 CFR 1.821-1.825."

□ 9. OTHER:

Direct the response and any questions about this notice to "Attention: Box Missing Parts."

A copy of this notice MUST be returned with the response.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). 6.5 The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing" An initial or substitute paper copyof the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703):308-1123 For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 308-6856